When was Clarity Pharmaceuticals founded?

Clarity Pharmaceuticals was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Clarity Pharmaceuticals located?

Clarity Pharmaceuticals is headquartered in Sydney, Australia.

How many employees does Clarity Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at Clarity Pharmaceuticals is 91.

Is Clarity Pharmaceuticals a funded company?

Clarity Pharmaceuticals is a funded company, having raised a total of $28.1M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2010.

When was the latest funding round of Clarity Pharmaceuticals?

Clarity Pharmaceuticals' latest funding was a $***** Post IPO round on Jul 28, 2025, with participation from 0 investor.

Where does Clarity Pharmaceuticals rank among its competitors?

Clarity Pharmaceuticals ranks 143rd amongst 2503 active competitors, of which 868 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Clarity Pharmaceuticals - 2026 Company Profile, Funding & Competitors

Q: Who are the top competitors of Clarity Pharmaceuticals?

Clarity Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Company Details

Developer of drugs to treat cancer. The company utilizes radiopharmaceutical technology for developing targeted therapies. The company has developed drug candidates used for the neuroendocrine tumour, neuroblastoma, colorectal, glioma, and prostate diseases. The company has also developed programs for companion diagnostics in the preclinical stage.

Key Metrics

Founded Year

2010

Location

Sydney, Australia

Stage

Public

Total Funding

$28.1M in 13 rounds

Latest Funding Round

Post IPO, Jul 28, 2025, $*****

Investors

ARC & 9 more

Ranked

143^rd among 2503 active competitors

Employee Count

91 as on Jun 30, 2026

Similar Companies

Molecular Partners & 95 more

Exit Details

Public

View Clarity Pharmaceuticals' full profile

Clarity Pharmaceuticals got listed on Aug 25, 2021.

Click here to take a look at Clarity Pharmaceuticals's IPO in detail

Clarity Pharmaceuticals has raised a total funding of $28.1M over 13 rounds. Its first funding round was on 2010. Clarity Pharmaceuticals has 10 institutional investors.

Here is the list of recent funding rounds of Clarity Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 28, 2025	4650017	Post IPO	8236281	6290006	5137721	3033324
Mar 26, 2024	6529616	Post IPO	4160721	7722557	1250630	7440087
Dec 15, 2020	4520892	Series B	3820861	9167151	5078402	3128077

Access funding benchmarks and valuations. Sign up today!

View details of Clarity Pharmaceuticals's funding rounds and investors

Clarity Pharmaceuticals' employee count trend

Clarity Pharmaceuticals has 91 employees as of Jun 26. Here is Clarity Pharmaceuticals's employee count trend over the years:

Employee count trend for Clarity Pharmaceuticals

Uncover Clarity Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Clarity Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Clarity Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
143rd	Clarity Pharmaceuticals 2010, Sydney (Australia), Public	Developer of drugs to treat cancer	$28.1M	ARC, University of Melbourne & 8 others	60/100